Monthly Archives: January 2005

DENVER, CO, January 17, 2005 – GlobeImmune and Mycologics announce today that they have signed a non-exclusive research license and option agreement under which Mycologics will pursue select antifungal products under the GlobeImmune Tarmogen Technology. The license agreement enables MycoLogics … Continue reading →

Aurora, CO, January 5, 2005  GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of two management team members. “We are pleased that GlobeImmune has been able to fill these two key positions,” said Timothy C. Rodell, M.D., GlobeImmune’s … Continue reading →